{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/irritable-bowel-syndrome/","result":{"data":{"firstChapter":{"id":"e08d84ab-7283-58cb-9873-bebac62d6494","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field 18b90d26-8b01-4974-a2d3-7cc779fefbd0 --><h1>Irritable bowel syndrome: Summary</h1><!-- end field 18b90d26-8b01-4974-a2d3-7cc779fefbd0 -->","htmlStringContent":"<!-- begin item 1baa5dae-c1d9-42ce-ac59-27de61b0909c --><!-- begin field 176d2f65-f2ac-4dfb-9e1b-7be54806cf10 --><ul><li>Irritable bowel syndrome (IBS) is a chronic, relapsing, and often lifelong disorder of the lower gastrointestinal tract, with no discernible structural or biochemical cause.</li><li>Typical clinical features are abdominal pain:<ul><li>Associated with a change in stool form and/or frequency.</li><li>Which may be related to defaecation, and there may be associated bloating.</li></ul></li><li>The exact underlying cause of IBS is unknown, but is likely to be multifactorial.</li><li>The global prevalence of IBS in the general population is estimated to be 5–20%.</li><li>The symptoms of IBS may fluctuate over years.</li><li>A diagnosis of IBS should be considered in a person who has had any<em> </em>of the following symptoms for at least 6 months:<ul><li>Abdominal pain, or</li><li>Bloating, or</li><li>Change in bowel habit.</li></ul></li><li>A diagnosis of IBS should be made if a person has abdominal pain which is either related to defecation, and/or associated with altered stool frequency (increased or decreased), and/or associated with altered stool form or appearance (hard, lumpy, loose, or watery); and<em> </em>there are at least two of the following:<ul><li>Alternative conditions with similar symptoms have been excluded.</li><li>Passage of rectal mucus, and</li><li>Symptoms worsened by eating.</li><li>Abdominal bloating (more common in women than men), distension, or hardness.</li><li>Altered stool passage (straining, urgency, or incomplete evacuation).</li></ul></li><li>The following investigations may be considered to exclude an alternative diagnosis.<ul><li>Full blood count (FBC).</li><li>Inflammatory markers such as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP).</li><li>Coeliac serology.</li><li>Note: IBS is a diagnosis of exclusion, there is no specific investigation to confirm a diagnosis.</li></ul></li><li>Initial management of a person with IBS should include:<ul><li>Providing advice and reassurance about the diagnosis, and offering sources of information and support.</li><li>Managing any associated stress, anxiety, and/or depression appropriately.</li><li>Advising the person to eat regular meals with a healthy, balanced diet, and to adjust their fibre intake according to symptoms.</li><li>Considering a trial of over-the-counter probiotic supplements for at least four weeks, if there are predominant symptoms of diarrhoea and/or bloating.</li><li>Trying soluble fibre supplements or foods high in soluble fibre if there are predominant symptoms of constipation.</li><li>Drinking an adequate fluid intake.</li><li>Encouraging regular physical activity.</li></ul></li><li>If symptoms persist despite initial dietary and lifestyle advice, further management options include a trial of:<ul><li>A bulk-forming laxative for constipation symptoms, with additional laxatives if needed.</li><li>Linaclotide for refractory constipation symptoms.</li><li>Loperamide for diarrhoea symptoms.</li><li>An antispasmodic drug for abdominal pain or spasm.</li><li>A low-dose tricyclic antidepressant (TCA) for refractory abdominal pain.</li><li>A selective serotonin reuptake inhibitor (SSRI) for refractory abdominal pain, if a TCA is ineffective, contraindicated, or not tolerated.</li></ul></li><li>If there is no alternative explanation for ongoing symptoms, specialist referral may be appropriate to:<ul><li>A gastroenterologist for further investigation.</li><li>A dietitian for specialist advice on single food avoidance and exclusion diets.</li><li>Mental health services for psychological support and intervention.</li></ul></li></ul><!-- end field 176d2f65-f2ac-4dfb-9e1b-7be54806cf10 --><!-- end item 1baa5dae-c1d9-42ce-ac59-27de61b0909c -->","topic":{"id":"4bb8acbd-d2b1-5f93-9ffa-0a3f11076292","topicId":"2c2fedc7-3daf-462e-b168-78c86cb2a2ec","topicName":"Irritable bowel syndrome","slug":"irritable-bowel-syndrome","aliases":[],"chapters":[{"id":"e08d84ab-7283-58cb-9873-bebac62d6494","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"09b06ced-d018-5c24-883c-ff37be197b2d","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"14d879ef-e87a-571a-a829-4f236e5265b8","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"0858c465-429d-5390-b8bd-432cb1d0fb46","slug":"changes","fullItemName":"Changes"},{"id":"fbcab9c4-bcb5-5d61-855f-1ec3aef8fdfe","slug":"update","fullItemName":"Update"}]},{"id":"d1d333cb-5ad0-5c55-987c-0d9bcdd7219b","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"df8485dd-d258-554e-91a1-cfae144c8f3a","slug":"goals","fullItemName":"Goals"},{"id":"92f70986-7a29-5aaf-8c2b-e24b675e84dc","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"4cbbe159-85f5-573d-a6f1-cf83b24c7513","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"b054d7f7-3303-57ad-bc98-df229e629e9c","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d5eb318d-cbd0-556b-8ce7-6c20aab02bc0","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c7ecf3c9-b183-5b40-99b8-9fa4ac12bfb8","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"156f0f16-df4f-5fcf-94da-2e9dfe0d9ae7","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"d091ffcd-a585-5def-b8a6-6a8e82be964d","slug":"definition","fullItemName":"Definition"},{"id":"08e0e6c7-a53c-53d9-a8ff-37b9af0475a9","slug":"causes","fullItemName":"Causes"},{"id":"2af080fe-338c-5682-927e-df91b2056310","slug":"prevalence","fullItemName":"Prevalence"},{"id":"668a8344-5367-57b6-be24-4904a8b84c09","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"d71af51f-0d21-583c-ae74-cdeefe5efe9a","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"1e13d165-63d9-5000-8411-3cb047828b3a","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"d335e933-3ba3-56d3-9f86-ccb100e2cb09","slug":"assessment","fullItemName":"Assessment"},{"id":"f6a63ea2-fb31-5f4c-b6ca-21ee922d5615","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"a0f45b9c-efa3-5c88-a5bc-3cd26c71883f","slug":"management","fullItemName":"Management","subChapters":[{"id":"d4748fe8-65f9-5b0b-bbd0-32469fde1c78","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"86d862ff-43f3-59ac-9769-c4bc0ec5ea9b","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"4517eb7c-ad75-5732-86b2-ea7cf18e7a93","slug":"bulk-forming-laxatives","fullItemName":"Bulk-forming laxatives"},{"id":"712646a9-5a89-5454-b98e-b2d2dce9ac3d","slug":"linaclotide","fullItemName":"Linaclotide"},{"id":"b36ea15d-0d7e-5080-9c77-f7f1b274523b","slug":"loperamide","fullItemName":"Loperamide"},{"id":"c7ea4d4a-3d5a-5cdb-8999-e01670699563","slug":"antispasmodic-drugs","fullItemName":"Antispasmodic drugs"},{"id":"b5eff265-676e-584f-a5d6-0a4714238d8f","slug":"antidepressant-drugs","fullItemName":"Antidepressant drugs"}]},{"id":"2c06aa30-84a6-5e94-8d6f-1d960d28dcdc","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"25c14e40-3957-5b26-aa34-0afc73225fdd","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"38e74c6b-daec-50bd-a23a-3aa30b83db82","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"c6497438-25eb-590a-9d9d-dfe08a17fb21","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"36885cba-cf5e-5cab-a474-2c0fc504fa91","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"89b5e4f9-0ed1-5b13-8258-3ba2b6f5b43e","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"d3199940-6be9-57b4-a2b0-2ee240db6d97","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"5667ce2f-151b-57f5-9fde-07b6339b1aef","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"4bb8acbd-d2b1-5f93-9ffa-0a3f11076292","topicId":"2c2fedc7-3daf-462e-b168-78c86cb2a2ec","topicName":"Irritable bowel syndrome","slug":"irritable-bowel-syndrome","aliases":[],"topicSummary":"Irritable bowel syndrome (IBS) is a chronic, relapsing, and often lifelong disorder of the lower gastrointestinal tract, with no structural cause","lastRevised":"Last revised in October 2020","nextPlannedReviewBy":"2022-10-01T00:00:00+01:00","nextPlannedReviewByDateTime":"2022-09","nextPlannedReviewByDisplay":"September 2022","specialities":[{"id":"e4fd15e3-ef70-523f-843c-5270742f518d","name":"Gastrointestinal","slug":"gastrointestinal"}],"chapters":[{"id":"e08d84ab-7283-58cb-9873-bebac62d6494","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"09b06ced-d018-5c24-883c-ff37be197b2d","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"14d879ef-e87a-571a-a829-4f236e5265b8","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"0858c465-429d-5390-b8bd-432cb1d0fb46","slug":"changes","fullItemName":"Changes"},{"id":"fbcab9c4-bcb5-5d61-855f-1ec3aef8fdfe","slug":"update","fullItemName":"Update"}]},{"id":"d1d333cb-5ad0-5c55-987c-0d9bcdd7219b","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"df8485dd-d258-554e-91a1-cfae144c8f3a","slug":"goals","fullItemName":"Goals"},{"id":"92f70986-7a29-5aaf-8c2b-e24b675e84dc","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"4cbbe159-85f5-573d-a6f1-cf83b24c7513","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"b054d7f7-3303-57ad-bc98-df229e629e9c","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d5eb318d-cbd0-556b-8ce7-6c20aab02bc0","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c7ecf3c9-b183-5b40-99b8-9fa4ac12bfb8","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"156f0f16-df4f-5fcf-94da-2e9dfe0d9ae7","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"d091ffcd-a585-5def-b8a6-6a8e82be964d","slug":"definition","fullItemName":"Definition"},{"id":"08e0e6c7-a53c-53d9-a8ff-37b9af0475a9","slug":"causes","fullItemName":"Causes"},{"id":"2af080fe-338c-5682-927e-df91b2056310","slug":"prevalence","fullItemName":"Prevalence"},{"id":"668a8344-5367-57b6-be24-4904a8b84c09","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"d71af51f-0d21-583c-ae74-cdeefe5efe9a","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"1e13d165-63d9-5000-8411-3cb047828b3a","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"d335e933-3ba3-56d3-9f86-ccb100e2cb09","slug":"assessment","fullItemName":"Assessment"},{"id":"f6a63ea2-fb31-5f4c-b6ca-21ee922d5615","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"a0f45b9c-efa3-5c88-a5bc-3cd26c71883f","slug":"management","fullItemName":"Management","subChapters":[{"id":"d4748fe8-65f9-5b0b-bbd0-32469fde1c78","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"86d862ff-43f3-59ac-9769-c4bc0ec5ea9b","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"4517eb7c-ad75-5732-86b2-ea7cf18e7a93","slug":"bulk-forming-laxatives","fullItemName":"Bulk-forming laxatives"},{"id":"712646a9-5a89-5454-b98e-b2d2dce9ac3d","slug":"linaclotide","fullItemName":"Linaclotide"},{"id":"b36ea15d-0d7e-5080-9c77-f7f1b274523b","slug":"loperamide","fullItemName":"Loperamide"},{"id":"c7ea4d4a-3d5a-5cdb-8999-e01670699563","slug":"antispasmodic-drugs","fullItemName":"Antispasmodic drugs"},{"id":"b5eff265-676e-584f-a5d6-0a4714238d8f","slug":"antidepressant-drugs","fullItemName":"Antidepressant drugs"}]},{"id":"2c06aa30-84a6-5e94-8d6f-1d960d28dcdc","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"25c14e40-3957-5b26-aa34-0afc73225fdd","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"38e74c6b-daec-50bd-a23a-3aa30b83db82","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"c6497438-25eb-590a-9d9d-dfe08a17fb21","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"36885cba-cf5e-5cab-a474-2c0fc504fa91","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"89b5e4f9-0ed1-5b13-8258-3ba2b6f5b43e","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"d3199940-6be9-57b4-a2b0-2ee240db6d97","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"5667ce2f-151b-57f5-9fde-07b6339b1aef","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"4bb8acbd-d2b1-5f93-9ffa-0a3f11076292"}},"staticQueryHashes":["3666801979"]}